| 2017-05-17 07:56:17 | Boston Scientific Lotus data positive, says RBC CapitalRBC Capital analyst Glenn Novarro says clinical data gives him confidence that Boston Scientific's Lotus platform "can become a viable competitor" in the U.S. The analyst keeps a $29 price target and an Outperform rating on the shares. | |
|---|---|---|
| ||
| , … |
| |
|---|---|---|
| ||
| | |
| | |
| |
| | |
| ||
| | |
| , |
| |
| , |
| |
| ||
| | |
| , … |
| |
| , |
| |
| |
| , … |
| |
|---|---|---|
| | |
| | |
| ||
| |
| | |
| , |
| |
| ||
| ||
|